Oxford University begins human trials for the world's first AI-designed vaccine, targeting Crimean-Congo haemorrhagic fever (CCHF), a deadly virus with 40% mortality rates and no widely approved vaccine, using AI to accelerate development by analyzing genetic data to identify immune response triggers.
CEPI and Gavi are investing over $100 million to accelerate the development of a vaccine against the Bundibugyo Ebola species, which is spreading in DRC and Uganda. The approved Ervebo vaccine targets a different strain, and new candidates face challenges including clinical trials in conflict zones and community distrust.
Russia and Cuba will sign a memorandum today for the joint development of cancer vaccines. Deputy Prime Minister Dmitry Chernyshenko announced this at the St. Petersburg International Economic Forum (SPIEF), where Russia also noted interest from 90 companies in supplying agricultural products to Cuba.
The Coalition for Epidemic Preparedness Innovations (CEPI) will provide $60 million to Moderna and two other organizations to accelerate the development of a vaccine against the Ebola Bundibugyo virus strain (BDBV), amid an outbreak in the Democratic Republic of Congo. Clinical trials could be ready within months, though challenges remain.
Anthropic and the Gates Foundation have committed $200 million over four years to support AI-driven public goods in global health, life sciences, education, and economic mobility, with initiatives including vaccine development, healthcare intelligence, educational tools, and agricultural productivity improvements.
